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INTRODUCTION
Chronic kidney disease (CKD) is a common diagnosis of major public health importance.
Defined as the presence of kidney damage or abnormal kidney function over a span of at least three months [1] , CKD has a prevalence of 13.6% in the United States making it more common than diabetes mellitus [2] . Furthermore, CKD is strongly associated with cardiovascular events [3] with the presence of CKD increasingly recognized as a coronary heart disease equivalent, similar to diabetes [4] . This enhanced cardiovascular risk increases with worsening stage of CKD, and the prevalence of advanced CKD with glomerular filtration rate (GFR) below 30 mL/min/1.73 m 2 is estimated at 0.62% of the population 2 .
In light of the high prevalence and associated cardiovascular complications of CKD, efforts to mitigate modifiable risk factors such as hypertension are needed. Indeed, hypertension is very common in CKD with a prevalence of 86% in a recent Chronic Renal Insufficiency Cohort (CRIC) report [5] . Notably, 58% of hypertensive CRIC patients were on treatment with at least 3 antihypertensive medications. Similarly, a recent prospective cohort study of 436 CKD patients employing ambulatory blood pressure monitoring (ABPM) found resistant hypertension to be prevalent in 23% [6] , emphasizing the difficulty of controlling BP in this population.
Thus control of hypertension is a primary concern in a large proportion of the CKD population and multiple medications are frequently necessary for adequate treatment. With a limited number of drug classes in the antihypertensive armamentarium, the use of thiazide diuretics is an attractive option. Unfortunately, for decades the conventional wisdom has been that thiazides are ineffective in advanced CKD and thus these medications are often overlooked in the CKD population; this thought still prevails. This review will examine the history of thiazide diuretic use in CKD, current guidelines, and the evidence for efficacy of thiazide use in advanced CKD. Notably, this review will update on recent reviews of this topic [7;8] , with a particular focus on the latest evidence from the last year.
THIAZIDE BACKGROUND
By definition thiazides are all derivatives of benzothiadiazine, which include chlorothiazide, hydrochlorothiazide, and bendroflumethiazide. Other agents that are pharmacologically similar are properly termed thiazide-like diuretics, which include metolazone, chlorthalidone, and indapamide. In this review "thiazides" refers both to benzothiadiazine derivatives and to thiazide-like diuretics, which is consistent with common practice.
Thiazides were the first category of effective oral antihypertensive drugs with an acceptable safety profile, and they have remained in clinical use since their discovery in the 1950s [9] . Thiazides improve cardiovascular endpoints including stroke, heart failure, coronary events, and death across numerous trials [10;11] . Considering the classical importance of volume overload to the pathogenesis of hypertension in kidney disease [12] , thiazides are ostensibly an attractive agent to use in CKD. However, for as long as thiazides have been in clinical use there has been concern that they may be ineffective in advanced CKD.
The reasons for this are both theoretical and empirical. Firstly, the primary site of action for thiazides is the Na+/Cl-cotransporter (NCC) in the distal convoluted tubule of the nephron, which is responsible for only 5% of total filtered sodium reabsorption. Thus in advanced CKD where GFR falls leading to reduced filtration of sodium, the presumption has been that inhibiting such a small fraction of total sodium reabsorption would be clinically insignificant. Secondly, small early studies of chlorothiazide in CKD appeared to support the theoretical concerns [13;14] . One such trial from 1961 epitomizes the early evidence base [14] . In this study chlorothiazide 500 mg was administered intravenously once to subjects who were then closely monitored for the subsequent 3 hours while on a constant intravenous saline infusion [14] . Urine flow and the sodium excretion rate increased in all 7 subjects with inulin clearance 60 mL/min or less. However, the 2 subjects with the lowest clearances at 6 and 11 mL/min did not have as great an improvement in urine flow or sodium excretion as the others. Based on these results, the authors concluded that thiazide efficacy is reduced in the setting of very low GFR. However, it should be noted that more recent investigators have suggested that the antihypertensive effect of thiazides may be due to a direct vasodilator effect [15;16] , which may in part explain the positive findings below.
GUIDELINES ON THIAZIDE USE IN CKD
Based on such qualified conclusions from early studies, a consensus developed that thiazide diuretics were ineffective in advanced CKD, and while there have been acknowledgments that the evidence wasn't definitive [17] , the dogma hardened and became , while the more recent Kidney Disease Improving Global Outcomes (KDIGO) guidelines are less dogmatic [21] . The KDIGO guidelines acknowledge that while many clinicians switch from thiazides to loop diuretics, the antihypertensive benefit of thiazides may still be preserved at low levels of GFR.
OLDER STUDIES OF THIAZIDES IN CKD
Starting in the 1970s numerous small trials began to show both diuretic and antihypertensive effects of varied thiazides in CKD. As detailed in Table 1 , these early studies included 5 small heterogeneous trials of metolazone in CKD all with a before-and-after design [22] [23] [24] [25] [26] , and in general GFR was low with 2 trials reporting creatinine clearances for individual subjects as low as 1 mL/min. These studies showed an improvement in reported diuretic or antihypertensive outcomes with metolazone administration, and these early positive results are likely the reason that there is a persistent belief that metolazone is the unique thiazide that is effective in advanced CKD [27] .
Two small trials from the 1980s with alternative thiazides showed further evidence of efficacy in advanced CKD. The first included 8 hypertensive patients with mean serum creatinine 3.31 mg/dL and all subjects were treated with furosemide and hydrochlorothiazide leading to significantly reduced body weight, plasma volume, and BP [28] . The second trial enrolled 15 hypertensive subjects including 5 with CKD and mean creatinine clearance of 37 mL/min1.73 m 2 who were all treated with escalating doses of indapamide, and those subjects with CKD had significantly greater reduction in body weight and similar reduction in BP as compared to those subjects with normal renal function [29] .
Importantly, 5 randomized controlled trials (RCT) reported between 1979 and 2012 have investigated thiazide efficacy in CKD [30] [31] [32] [33] [34] , also detailed in Table 1 . The earliest was a double blind crossover study that enrolled 16 woman with mean creatinine clearance of 14 mL/min/1.73 m 2 who were treated with chlorothiazide 500 mg twice daily or placebo for 6 weeks before crossover [30] . Seven patients were withdrawn by protocol, but chlorothiazide significantly reduced BP in the 9 subjects that completed the study.
Two similar RCTs from the 1990s investigated natriuresis due to thiazides, loop diuretics, or the combination in a single blind, crossover fashion. The first enrolled 10 subjects with mean inulin clearance 13 mL/min/1.73 m 2 who were treated with single intravenous doses of either a loop diuretic alone or combined with intravenous isobutyl hydrochlorothiazide; the combination significantly increased sodium excretion [31] . The second RCT enrolled 19 subjects with average creatinine clearance 39 mL/min and treated them with single oral doses of either a loop diuretic, or oral hydrochlorothiazide, or the combination of the two. This trial found that while the loop diuretic and hydrochlorothiazide individually increased sodium excretion, the combination was subsequently significantly more potent [32] .
In the last 10 years Dussol and colleagues performed two similar double blind RCTs of thiazides in CKD, both also with a crossover design [33;34] . The first RCT enrolled 7 subjects with average measured GFR of 25 mL/min who were randomized to either oral furosemide 60 mg daily or oral hydrochlorothiazide 25 mg daily for 30 days. After washout they then crossed over to the other drug. Finally, they received 30 day period of combination therapy [33] . The second RCT was reported in 2012 and enrolled 23 subjects with measured GFR of 25 mL/min [34] . This second RCT used the same doses of both medications, but the intervention periods were each 90 days long. Both RCTs found furosemide and hydrochlorothiazide individually significantly and similarly reduced mean arterial BP with the combination of diuretics more potent in the larger study for a reduction of 15 mmHg.
RECENT STUDIES OF CHLORTHALIDONE IN CKD
The positive studies of thiazides in CKD above have included most clinically available examples of the drug class including chlorothiazide, metolazone, hydrochlorothiazide, and indapamide. However, the absence of chlorthalidone is conspicuous as there is ample direct RCT evidence for the benefit of chlorthalidone in the general hypertensive population including from the Systolic Hypertension in the Elderly Program (SHEP) trial [35] and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [36] . More recently, post hoc analyses of the Multiple Risk Factor Invention Trial (MR FIT) suggest that chlorthalidone may be superior to hydrochlorothiazide for regression of left ventricular hypertrophy [37] and reduction of cardiovascular events [38] . It is in this context that two trials of chlorthalidone in CKD published in the last year merit close attention.
Both studies were uncontrolled trials using a before and after design. 12 of 14 subjects completed the study; one subject withdrew consent after 2 days of treatment and another was excluded per protocol 2 weeks into treatment due to home BP persistently elevated > 160/100 mmHg [**39]. All subjects were male, average age was 67. It is important to note that laboratory abnormalities and adverse events were common in both studies with 50% of subjects in the forced titration study of 14 subjects with advanced CKD [**39] and in 15% of patients in the fixed dose study with less severe CKD [**40]. Not surprisingly, the most frequent complications in both studies were hypokalemia, hyponatremia, and hyperuricemia.
CONCLUSION
The early observation that thiazide potency is reduced in advanced CKD is uncontroversial, especially as it has since been widely recognized that loop diuretic potency too is reduced in advanced CKD [41] . However, that early observation developed into dogma reinforced by influential guidelines that thiazides are ineffective in advanced CKD. Over the span of decades varied small studies using multiple different thiazides and including 5 RCTs for a large study size relative to prior trials.
The time has come to perform a randomized trial of safety and efficacy of thiazides on top of existing antihypertensive among hypertensive people with advanced CKD.
• Thiazides have been shown to be effective for reducing blood pressure in advanced chronic kidney disease in small studies, including randomized trials.
• Thiazides have been shown to be effective for natriuresis in advanced chronic kidney disease in small studies, including randomized trials.
• Most clinically available thiazides have direct evidence for efficacy in advanced chronic kidney disease, not just metolazone.
